Asbestosis Clinical Trial
Official title:
Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
This study aims at determining the the efficiency and prognosis of using pirfenidone drug among asbestosis patients.
Asbestos exposure is associated with pleural and lung fibrosis and lung cancer. It has pathomechanisms and clinical similarities to interstitial pulmonary fibrosis disease. There is no definite cure for asbestosis. Pirfenidone has antifibrotic and anti-inflammatory effects.The safety and effectiveness of pirfenidone for the treatment of non-interstitial pulmonary fibrosis progressive fibrotic interstitial lung diseases remain unclear including asbestosis. Only few studies for pirfenidone use in asbestosis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04161014 -
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
|
Phase 2 | |
| Recruiting |
NCT02748798 -
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
|
Early Phase 1 | |
| Recruiting |
NCT02280343 -
Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis
|
N/A | |
| Completed |
NCT00005280 -
Specialized Center of Research in Occupational and Immunologic Lung Disease
|
N/A | |
| Enrolling by invitation |
NCT04016181 -
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
|